Frontline chemoimmunotherapy with fludarabin (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international randomized study of the German CLL Study Group (GCLLSG) (CLL10 study).

Authors
Category Primary study
JournalBlood
Year 2014
This article has no abstract
Epistemonikos ID: 7e5415d572729a155ec87cfa3fb7b4fd172c8e88
First added on: Oct 13, 2018